MX2018014573A - Vacuna contra el virus del zika. - Google Patents
Vacuna contra el virus del zika.Info
- Publication number
- MX2018014573A MX2018014573A MX2018014573A MX2018014573A MX2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- polypeptides
- artificial nucleic
- zika virus
- virus vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se dirige a un ácido nucleico artificial y a polipéptidos adecuados para su uso en el tratamiento o profilaxis de una infección con Virus del Zika o un trastorno relacionado con dicha infección. En particular, la presente invención se refiera a una vacuna del virus del Zika. La presente invención se dirige a un ácido nucleico artificial, polipéptidos, composiciones y vacunas que comprenden al ácido nucleico artificial o los polipéptidos. La invención además se refiere a un método para tratar o prevenir un trastorno o una enfermedad, primeros y segundos usos médicos del ácido nucleico artificial, polipéptidos, composiciones y vacunas. Además, la invención se dirige a un kit, particularmente a un kit de partes, que comprenden al ácido nucleico artificial, polipéptidos, composiciones y vacunas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2016053398 | 2016-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014573A true MX2018014573A (es) | 2019-09-04 |
Family
ID=55398295
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009917A MX2018009917A (es) | 2016-02-17 | 2017-02-17 | Vacuna contra el virus del zika. |
MX2018014573A MX2018014573A (es) | 2016-02-17 | 2018-08-15 | Vacuna contra el virus del zika. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009917A MX2018009917A (es) | 2016-02-17 | 2017-02-17 | Vacuna contra el virus del zika. |
Country Status (6)
Country | Link |
---|---|
US (2) | US11723967B2 (es) |
EP (1) | EP3416683A1 (es) |
BR (1) | BR112018016755A2 (es) |
MX (2) | MX2018009917A (es) |
SG (2) | SG11201806340YA (es) |
WO (1) | WO2017140905A1 (es) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
SG10201710473VA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
WO2015024665A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Rabies vaccine |
KR20160044566A (ko) | 2013-08-21 | 2016-04-25 | 큐어백 아게 | 호흡기 세포융합 바이러스 |
CA3179824A1 (en) | 2014-06-25 | 2015-12-30 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
PL4023755T3 (pl) | 2014-12-12 | 2023-12-27 | CureVac SE | Sztuczne cząsteczki kwasu nukleinowego dla poprawy ekspresji białka |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
JP7072386B2 (ja) | 2015-06-29 | 2022-05-20 | アクイタス セラピューティクス インコーポレイテッド | 核酸の送達のための脂質および脂質ナノ粒子製剤 |
TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
FI3368507T3 (fi) | 2015-10-28 | 2023-03-21 | Acuitas Therapeutics Inc | Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi |
US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
MX2018009917A (es) | 2016-02-17 | 2019-08-14 | Curevac Ag | Vacuna contra el virus del zika. |
BR112018017307A2 (pt) * | 2016-02-25 | 2019-01-08 | Univ Pennsylvania | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
BR112018075440A2 (pt) | 2016-06-09 | 2019-04-02 | Beth Israel Deaconess Medical Center | composições e métodos para prevenir e tratar a infecção por zika vírus |
MX2018013919A (es) | 2016-06-09 | 2019-04-15 | Curevac Ag | Portadores hibridos para cargas de acido nucleico. |
EP3497246A1 (en) * | 2016-08-08 | 2019-06-19 | The Secretary of State for Health | Flavivirus diagnostic assay |
CA3036892A1 (en) | 2016-09-16 | 2018-03-22 | Pebble Labs Usa Inc. | Novel paratransgenic system for the biocontrol of disease-transmitting mosquitos |
WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
WO2018102659A1 (en) * | 2016-12-01 | 2018-06-07 | The Trustees Of Columbia University In The City Of New York | Serological assay for zika virus infection |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
JP2020501545A (ja) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのrna |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
US11524066B2 (en) | 2016-12-23 | 2022-12-13 | CureVac SE | Henipavirus vaccine |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
MA47515A (fr) * | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
AU2018258575A1 (en) | 2017-04-27 | 2019-11-07 | The Johns Hopkins University | Hepatitis C virus gene sequences and methods of use therefor |
CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
RU2020103379A (ru) | 2017-07-04 | 2021-08-04 | Куревак Аг | Новые молекулы нуклеиновых кислот |
EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
CA3073018A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | VACCINE AGAINST BUNYAVIRUS |
WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
US11426457B2 (en) | 2017-09-21 | 2022-08-30 | Emergex Vaccines Holding Limited | MHC class I associated peptides for prevention and treatment of zika virus |
CA3073634A1 (en) | 2017-10-19 | 2019-04-25 | Curevac Ag | Novel artificial nucleic acid molecules |
CA3081581A1 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Method for inactivating zika virus and for determining the completeness of inactivation |
RU2020117848A (ru) | 2017-11-08 | 2021-12-08 | Куревак Аг | Адаптиция последовательности phk |
MX2020004833A (es) * | 2017-11-09 | 2021-01-08 | Pasteur Institut | Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. |
US11739348B2 (en) | 2017-11-10 | 2023-08-29 | The Research Institute At Nationwide Children's Hospital | Recombinant vectors encoding Zika virus protein subunits |
WO2019108970A1 (en) | 2017-11-30 | 2019-06-06 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
EP3729093A1 (en) * | 2017-12-21 | 2020-10-28 | Pepperprint GmbH | Ns2b as marker for zika virus infections |
CN108210921A (zh) * | 2017-12-29 | 2018-06-29 | 广州恩宝生物医药科技有限公司 | 一种寨卡病毒疫苗及其制备方法 |
MX2020006357A (es) * | 2018-01-06 | 2020-08-17 | Emergex Vaccines Holding Ltd | Peptidos asociados al mhc de clase i para la prevencion y el tratamiento de multiples flavivirus. |
CN108484737B (zh) * | 2018-02-09 | 2021-04-23 | 四川农业大学 | 坦布苏病毒非结构蛋白ns4b截短蛋白的表达方法及其产品和应用 |
AU2019244435A1 (en) * | 2018-03-29 | 2020-10-15 | Emergex Vaccines Holding Limited | Vaccine compositions |
EP3826672A4 (en) | 2018-07-23 | 2022-04-20 | The University of Adelaide | VACCINE AGAINST THE ZIKA VIRUS |
US11702453B2 (en) | 2018-08-21 | 2023-07-18 | Regents Of The University Of Michigan | Materials and methods for inhibiting flavivirus infection |
EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | HIV RNA VACCINE |
US20230090515A1 (en) | 2019-12-20 | 2023-03-23 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
US20240277830A1 (en) | 2020-02-04 | 2024-08-22 | CureVac SE | Coronavirus vaccine |
WO2021158815A1 (en) * | 2020-02-05 | 2021-08-12 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
BR112022017429A2 (pt) * | 2020-03-03 | 2022-11-29 | Mayo Found Medical Education & Res | Polipeptídeos do zika vírus |
CN111514286B (zh) * | 2020-04-01 | 2022-03-08 | 中国科学院过程工程研究所 | 一种寨卡病毒e蛋白结合疫苗及其制备方法 |
KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
BR112023012303A2 (pt) | 2020-12-22 | 2024-02-15 | CureVac SE | Vacina de rna contra variantes de sars-cov-2 |
CU20210063A7 (es) * | 2021-07-28 | 2023-03-07 | Ct Ingenieria Genetica Biotecnologia | Antígeno recombinante para la inducción de respuesta inmune contra el virus zika |
CN118176204A (zh) | 2021-08-11 | 2024-06-11 | 圣诺菲·帕斯图尔公司 | 截短的流感神经氨酸酶及其使用方法 |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery |
WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE50202634D1 (de) | 2001-06-05 | 2005-05-04 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
MX2010008468A (es) | 2008-01-31 | 2010-08-30 | Curevac Gmbh | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US8691961B1 (en) | 2009-11-09 | 2014-04-08 | Integral Molecular, Inc. | Flavivirus reporter virus and methods of making and using the same |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
JP5948327B2 (ja) | 2010-07-30 | 2016-07-06 | キュアヴァック アーゲー | トランスフェクションおよび免疫刺激のためのジスルフィド架橋されたカチオン性成分との核酸の複合体形成 |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
ES2660129T3 (es) | 2012-03-27 | 2018-03-20 | Curevac Ag | Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP |
ES2654205T3 (es) | 2012-03-27 | 2018-02-12 | Curevac Ag | Moléculas artificiales de ácido nucleico para la expresión mejorada de proteínas o péptidos |
AU2013242403B2 (en) | 2012-03-27 | 2018-10-18 | Curevac Ag | Artificial nucleic acid molecules |
US20150306249A1 (en) | 2012-05-25 | 2015-10-29 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
SG10201710473VA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
KR20160044566A (ko) | 2013-08-21 | 2016-04-25 | 큐어백 아게 | 호흡기 세포융합 바이러스 |
MX2016002153A (es) | 2013-08-21 | 2017-03-01 | Curevac Ag | Composicion y vacuna para tratar cancer de prostata. |
WO2015024665A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Rabies vaccine |
PE20160224A1 (es) | 2013-08-21 | 2016-05-14 | Curevac Ag | Composicion y vacuna para tratar cancer de pulmon |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
SG10201903381TA (en) | 2013-12-30 | 2019-05-30 | Curevac Ag | Artificial nucleic acid molecules |
SG10201805660WA (en) | 2013-12-30 | 2018-08-30 | Curevac Ag | Methods for rna analysis |
WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
EP3129050A2 (en) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
EP3521456B1 (en) | 2014-06-10 | 2023-01-04 | CureVac Manufacturing GmbH | Methods and means for enhancing rna production |
PL4023755T3 (pl) | 2014-12-12 | 2023-12-27 | CureVac SE | Sztuczne cząsteczki kwasu nukleinowego dla poprawy ekspresji białka |
WO2016097065A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
US20180148727A1 (en) | 2014-12-30 | 2018-05-31 | Curevac Ag | Artificial nucleic acid molecules |
WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
EP3283125B1 (en) | 2015-04-17 | 2021-12-29 | CureVac Real Estate GmbH | Lyophilization of rna |
TWI739740B (zh) | 2015-04-22 | 2021-09-21 | 德商奎爾法克股份有限公司 | 用於治療腫瘤疾病之含有rna的組成物 |
SG11201708867UA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Immobilized poly(n)polymerase |
US20180208957A1 (en) | 2015-04-30 | 2018-07-26 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
DK3294885T3 (da) | 2015-05-08 | 2020-08-10 | Curevac Real Estate Gmbh | Fremgangsmåde til at fremstille rna |
US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
CN107530448A (zh) | 2015-05-20 | 2018-01-02 | 库瑞瓦格股份公司 | 包含长链rna的干粉组合物 |
WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
EP3303575B1 (en) | 2015-05-29 | 2022-03-16 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
WO2016203025A1 (en) | 2015-06-17 | 2016-12-22 | Curevac Ag | Vaccine composition |
WO2016210127A1 (en) | 2015-06-25 | 2016-12-29 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
WO2017001058A1 (en) | 2015-07-01 | 2017-01-05 | Curevac Ag | Method for analysis of an rna molecule |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
TW201718638A (zh) * | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
WO2017021546A1 (en) | 2015-08-05 | 2017-02-09 | Curevac Ag | Epidermal mrna vaccine |
EP3699288A1 (en) | 2015-08-07 | 2020-08-26 | CureVac AG | Process for the in vivo production of rna in a host cell |
ES2837100T3 (es) | 2015-08-10 | 2021-06-29 | Curevac Real Estate Gmbh | Método de aumento de la replicación de una molécula de ADN circular |
ES2924739T3 (es) | 2015-08-28 | 2022-10-10 | Curevac Ag | Moléculas de ácido nucleico artificiales |
US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
US11413346B2 (en) | 2015-11-09 | 2022-08-16 | Curevac Ag | Rotavirus vaccines |
WO2017081082A2 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
EP3394237A1 (en) | 2015-12-21 | 2018-10-31 | CureVac AG | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
EP3414340B1 (en) | 2016-02-12 | 2023-08-09 | CureVac SE | Method for analyzing rna |
US20190049414A1 (en) | 2016-02-15 | 2019-02-14 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
MX2018009917A (es) | 2016-02-17 | 2019-08-14 | Curevac Ag | Vacuna contra el virus del zika. |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
US20170354729A1 (en) * | 2016-03-16 | 2017-12-14 | Novavax, Inc. | Vaccine compositions containing modified zika virus antigens |
WO2017162297A1 (en) | 2016-03-24 | 2017-09-28 | Curevac Ag | Immobilized inorganic pyrophosphatase (ppase) |
WO2017182634A1 (en) | 2016-04-22 | 2017-10-26 | Curevac Ag | Rna encoding a tumor antigen |
WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
WO2017191258A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Influenza mrna vaccines |
US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
EP3464619A1 (en) | 2016-05-25 | 2019-04-10 | CureVac AG | Novel biomarkers |
US20190381180A1 (en) | 2016-06-09 | 2019-12-19 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
EP3468609A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Cationic carriers for nucleic acid delivery |
MX2018013919A (es) | 2016-06-09 | 2019-04-15 | Curevac Ag | Portadores hibridos para cargas de acido nucleico. |
WO2017212006A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
KR20190039969A (ko) | 2016-08-19 | 2019-04-16 | 큐어백 아게 | 암 치료법을 위한 rna |
US10898566B2 (en) * | 2016-09-19 | 2021-01-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zika virus vaccines |
IL301800A (en) | 2016-10-26 | 2023-05-01 | Curevac Ag | mRNA vaccines with lipid nanoparticles |
WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
JP2020501545A (ja) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのrna |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
US11524066B2 (en) | 2016-12-23 | 2022-12-13 | CureVac SE | Henipavirus vaccine |
WO2018132537A1 (en) | 2017-01-11 | 2018-07-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an immune response against zika virus |
CN110392577A (zh) | 2017-03-17 | 2019-10-29 | 库尔维科公司 | 用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂 |
EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
RU2020103379A (ru) | 2017-07-04 | 2021-08-04 | Куревак Аг | Новые молекулы нуклеиновых кислот |
WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | VACCINE AGAINST BUNYAVIRUS |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
US20210361761A1 (en) | 2018-04-05 | 2021-11-25 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
JP2021519595A (ja) | 2018-04-17 | 2021-08-12 | キュアバック アーゲー | 新規rsv rna分子及びワクチン接種用組成物 |
EP4273266A3 (en) | 2018-06-28 | 2024-03-13 | CureVac RNA Printer GmbH | Bioreactor for rna in vitro transcription |
WO2020127959A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
BR112021009422A2 (pt) | 2018-12-21 | 2021-10-26 | Curevac Ag | Rna para vacinas contra malária |
AU2021206307A1 (en) | 2020-01-11 | 2022-09-08 | Sivec Biotechnologies Llc | A microbial system for production and delivery of eukaryote-translatable mRNA to eukarya |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
WO2021211343A1 (en) | 2020-04-13 | 2021-10-21 | Modernatx, Inc. | Zika virus mrna vaccines |
-
2017
- 2017-02-17 MX MX2018009917A patent/MX2018009917A/es unknown
- 2017-02-17 SG SG11201806340YA patent/SG11201806340YA/en unknown
- 2017-02-17 WO PCT/EP2017/053721 patent/WO2017140905A1/en active Application Filing
- 2017-02-17 SG SG10201913630YA patent/SG10201913630YA/en unknown
- 2017-02-17 US US15/999,469 patent/US11723967B2/en active Active
- 2017-02-17 BR BR112018016755A patent/BR112018016755A2/pt unknown
- 2017-02-17 EP EP17706710.5A patent/EP3416683A1/en active Pending
-
2018
- 2018-08-15 MX MX2018014573A patent/MX2018014573A/es unknown
-
2023
- 2023-06-21 US US18/338,612 patent/US20240024453A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210205434A1 (en) | 2021-07-08 |
MX2018009917A (es) | 2019-08-14 |
SG11201806340YA (en) | 2018-09-27 |
US20240024453A1 (en) | 2024-01-25 |
US11723967B2 (en) | 2023-08-15 |
BR112018016755A2 (pt) | 2018-12-26 |
SG10201913630YA (en) | 2020-03-30 |
WO2017140905A1 (en) | 2017-08-24 |
EP3416683A1 (en) | 2018-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018014573A (es) | Vacuna contra el virus del zika. | |
WO2018115507A3 (en) | Henipavirus vaccine | |
MX2020010941A (es) | Moleculas y composiciones novedosas de arn de vsr para vacunacion. | |
MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
WO2019193183A3 (en) | Novel yellow fever nucleic acid molecules for vaccination | |
EP4233898A3 (en) | Influenza mrna vaccines | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
CO2017012454A2 (es) | Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia | |
MX2018005230A (es) | Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon. | |
PH12017502233A1 (en) | Formulations for neoplasia vaccines and methods of preparing thereof | |
MX2016016722A (es) | Coronavirus. | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
PH12020500080A1 (en) | Senecavirus a immunogenic compositions and methods thereof | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
BR112022005687A2 (pt) | Vacinas contra o hbv e métodos para tratar o hbv | |
CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. | |
PH12017500450A1 (en) | Flavivirus virus like particle | |
MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
MX2017013879A (es) | Composiciones que comprenden anakinra. | |
EA201691458A1 (ru) | Составы для доставки в тонкую кишку |